ABOUT US Board Of Directors / Management PETER ISDALE, AM, BA (Hons), PhD, MAICD Dr Isdale was appointed Chief Executive Officer of IMBcom Pty Ltd in 2003. He is a member of the board of the Institute for Molecular Bioscience, a director of ElaCor Pty Ltd, Nephrogenix Pty Ltd, Kalthera Pty Ltd, Chairman of the Wetlands and Grasslands Foundation, non-executive Director of the Great Barrier Reef Research Foundation. He is an Adjunct professor at Texas A&M University and is a Senior Fellow of the Chaiyong Limthongkul Foundation (Thailand). Dr Isdale spent 15 years as a marine scientist before being appointed Business Director and senior executive at the Australian Institute of Marine Science. He has had 20 years of directorship on Boards of private, public and ASX-listed companies in Australia, Asia and the Pacific Rim. Peter was awarded as a Member in the General Division of the Order of Australia in 2006 for service to marine science through research and as a contributor to the development and commercialisation of biotechnology. DAVID LYSTER David is responsible for the co-ordination and business development activities in the Victorian College of Pharmacy at Monash University. David brings more than 10 years experience in the commercialisation of early stage, high-risk intellectual property to the board of Nephrogenix. David is actively involved in the Biotech field and has a private technology consulting business providing services to other Australian universities and the private sector. David is a director of two other companies involved in the commercialisation of early stage technologies. MELISSA LITTLE Professor Little is a founding scientist and director of Nephrogenix with extensive scientific expertise in the area of cancer genetics and kidney development. With publications in prestigious journals such as Science, Nature Genetics and Proceedings of the National Academy of Science (USA) and a number of patents, her work in understanding kidney development and kidney disease processes will eventually result in new treatments for renal disease through its commercialisation by Nephrogenix. Melissa’s professional history is littered with fellowships, including a Royal Society Endeavour Fellowship, AMRAD Postdoctoral Award and R. Douglas Wright Postdoctoral Fellowship and more recently the Gottschalk Medal. Melissa has been strongly involved in the development of medical research in Australia through her membership on the Health and Medical Research Strategic (Wills) Review and the Implementation Committee of that review. She has served on the NHMRC Training Awards Committee and as a member of the Consultative Panel created to guide the process of National Priority Setting. She has been instrumental in the initiation of Nephrogenix and has been the primary driver of this process. She will bring a wealth of scientific and research management experience to the Board of Nephrogenix. MICHAEL LUSIS, Executive Officer and Company Secretary Michael has completed B.LLB, B.Com (hons) and B.Sc (hons) degrees from the University of Queensland and is currently completing a PhD at the IMB. Previously, as an executive director of investment bank UBS, Michael gained extensive experience in advising companies on strategy, partnering, mergers and acquisitions and capital raising. Other commercial experience includes working as a management consultant with LEK Partnership and as a consultant with IMBcom.